high rheumatoid factor (RF) titers, and the presence of anti-SSA were associated with an increased risk for RA-CPFE. Additionally, levels of IgG and IgM autoantibodies to HBEC were elevated in RA-CPFE ...

The last dilution which yields a positive result (i.e., fluorescence observed under the microscope) is the titer that is reported. Antinuclear antibodies are found in people with various autoimmune ...

Regeneron Pharmaceuticals (NASDAQ ... The main reason is the extremely high competition in the PD-1/PD-L1 checkpoint inhibitors market, which includes Merck's Keytruda, Bristol-Myers Squibb's ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

“Meaning I'd hide a pack of cigarettes on a high cupboard shelf and only smoke if I was sure ... The treatment Lyn refers to is the monoclonal antibody dupilumab (brand name Dupixent), which works by ...

A high-yield savings account is a federally insured account to save money for short-term goals or needs, while still earning an above-average annual percentage yield — compared to traditional ...

A high potassium level can occur if you have certain health conditions, including kidney disease or heart failure. But it can also have other causes, including certain medications and heavy ...

Table 1. Overview of studies on hyposensitization of people with allergic contact dermatitis caused by sensitizers other than Rhus and nickel. One patient: remission of MF, no further need to ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The ...

Commissions do not affect our editors' opinions or evaluations. High-yield checking accounts offer debit cards, check-writing privileges and above-average interest rates. The best high-yield ...

More than 1,000,000 patients are currently being treated with Dupixent globally. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab ...